While the direct mechanism by which serum Bcl-2 impacts lung cancer cell apoptosis is not fully elucidated, elevated levels of circulating Bcl-2 could potentially reflect a higher tumor burden or a greater overall anti-apoptotic activity within the tumor, which might indirectly correlate with disease progression or response to therapy. This evidence concerns the gene BCL2 and neoplasm.